Big pharma and biotech are moving fast on myositis. More than forty companies now have over forty five therapies in the pipeline for these rare muscle diseases. The pace has picked up. In the last few months, both established firms and startups have launched high-stakes clinical trials.
As of September 2026, Boehringer Ingelheim registered and updated its phase III VERANDA-IIM trial, evaluating oral nerandomilast in adults with active idiopathic inflammatory myopathies over 52 weeks in a randomized, double-blind, placebo-controlled design.
Cell therapy is joining the race. Cabaletta Bio announced a phase 1/2 study of CABA-201, a cell therapy given with cyclophosphamide and fludarabine. This is for patients with active disease across several myositis subtypes. Priovant Therapeutics Inc. launched a phase 3, multicenter, double-blind study of brepocitinib, a TYK2/JAK1 inhibitor, in adults with dermatomyositis. Responders can join an open-label extension. Pfizer is also active. They are running a phase 3 trial of PF-06823859 (dazukibart) to see its effect on muscle inflammation and skin symptoms in idiopathic inflammatory myopathies.
The field is crowded. Pfizer, Galapagos NV, Fate Therapeutics, Artiva Biotherapeutics, Inc., Aavogen, CRISPR Therapeutics, Century Therapeutics, Inc., Cabaletta Bio, Miltenyi Biotec GmbH, Nkarta, Inc., Kyverna Therapeutics, Gilead Sciences, Bristol-Myers Squibb, Allogene Therapeutics, Adicet Therapeutics, and others are all pushing new candidates. The pipeline includes HuABC2, PF1801, PN-101, M5049, Descartes-08, Ophthalmic Emulsion, Emapalumab, and GB-0998.
By late September 2026, Janssen's Nipocalimab program remained active, with 57 clinical centers across 12 countries and a target enrollment of 36 patients, reflecting the global scale and ongoing commitment to myositis research.
Some drugs are drawing extra attention. Pfizer’s PF-06823859, a humanized monoclonal antibody that targets interferon-beta, is in phase III for dermatomyositis and polymyositis. Galapagos NV’s GLPG3667, an oral TYK2 inhibitor, is in phase II. Fate Therapeutics’ FT819, an allogeneic CAR T-cell therapy for CD19-positive B cells, is in phase I. The pipeline is broad. There are many molecule types, different ways to give the drugs, and varied clinical strategies. DelveInsight’s latest report covers these details.
DelveInsight’s commercial analysis shows just how much money and teamwork are shaping myositis drug development. The report tracks active and inactive programs, breaks down development stages, and maps out licensing and financing deals. The market is changing fast.
This burst of myositis research matches what’s happening in other rare diseases. More industry players are speeding up innovation. As reported earlier for B cell non Hodgkin lymphoma, new trials and therapies are changing the competitive field and raising standards for clinical proof.
Now, more than forty companies are racing to bring next-generation myositis drugs to market. The field is moving fast. There are more options than ever. Monoclonal antibodies, cell therapies, and small molecules are all in play. The old days of slow progress are over. For patients and doctors, the pipeline is bigger and smarter. There is real hope for targeted, effective treatments for diseases that have long had few options. The industry is betting big on rare disease trials. Myositis is no longer a neglected field. It is now a key front for science and business.
